Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to TradeZacks Investment Research • 01/31/24
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in HumansGlobeNewsWire • 01/24/24
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in SchizophreniaGlobeNewsWire • 01/16/24
Anavex (AVXL): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 01/09/24
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental DisordersGlobeNewsWire • 01/08/24
Anavex Life Sciences shares tank on Rett Syndrome trial results but analysts remain positiveProactive Investors • 01/04/24
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett SyndromeGlobeNewsWire • 12/20/23
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's DiseaseGlobeNewsWire • 12/19/23
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?Zacks Investment Research • 12/18/23
Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?Zacks Investment Research • 11/30/23
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business UpdateGlobeNewsWire • 11/27/23
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023GlobeNewsWire • 11/24/23
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or AnxietyGlobeNewsWire • 11/22/23
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer's DiseaseGlobeNewsWire • 10/25/23